A client of Winnipeg-based Company has claimed the company to be fraudulent, as it had publicised its ability to improve the lives of Multiple Sclerosis patients through stem cell therapy.
The CEO of Regenetek Research Inc for treatment collects thousands of dollars from Canadian patients.
Multiple Sclerosis
Multiple sclerosis can be a severely disabling autoimmune disease that affects the myelin or insulating layer of the nerve fibers and typically has remissions and relapses
Advertisement
Lee Chuckry, 47 is one among the patients questioning the research and credentials. He has been living with MS for nearly two decades.
"MS just keeps progressing, that's what it does. Hopefully I could stop it. That was my ultimate goal," Chuckry said in an interview with CTV News.
![Multiple Sclerosis Treatment and Modify]( "Multiple Sclerosis Treatment and Modify")
Multiple sclerosis is treated with drugs that modify the course of the disease, suppress immunity and relieve symptoms.
His efforts led him to Regenetek, and it's CEO: Doug Broeska. For $35,000, Regenetek patients were flown to India for the procedure. Chuckry was one of the participants. But when he returned home, he says his symptoms worsened.
In testimonials, MS patients attributed miraculous medical improvement to experimental stem cell therapy.
"I'm going to call Doug a con artist," Chuckry said. "You are preying on people who are desperate. They are looking for hope of any sort."
The University of Manitoba where Broeska claimed he received his degree and doctorate from has said there is no record of him graduating. He operates as a medical researcher without proper credentials.
None of the allegations have been proven in court, and Broeska has not been criminally charged. In a statement to CTV News, Regenetek wrote, "Its clinical study is being mischaracterized in the media."
While clinical trials are underway in Canada, doctors do not require patients to pay thousands of dollars to take part and no stem cell therapy has received Health Canada approval for treatment of Multiple Sclerosis.
Source: Medindia
Multiple Sclerosis Treatment and Modify
Multiple sclerosis is treated with drugs that modify the course of the disease, suppress immunity and relieve symptoms.
Advertisement
His efforts led him to Regenetek, and it's CEO: Doug Broeska. For $35,000, Regenetek patients were flown to India for the procedure. Chuckry was one of the participants. But when he returned home, he says his symptoms worsened.
In testimonials, MS patients attributed miraculous medical improvement to experimental stem cell therapy.
"I'm going to call Doug a con artist," Chuckry said. "You are preying on people who are desperate. They are looking for hope of any sort."
The University of Manitoba where Broeska claimed he received his degree and doctorate from has said there is no record of him graduating. He operates as a medical researcher without proper credentials.
None of the allegations have been proven in court, and Broeska has not been criminally charged. In a statement to CTV News, Regenetek wrote, "Its clinical study is being mischaracterized in the media."
While clinical trials are underway in Canada, doctors do not require patients to pay thousands of dollars to take part and no stem cell therapy has received Health Canada approval for treatment of Multiple Sclerosis.
Source: Medindia
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Genetics & Stem Cells News
Can stem cell therapy cure fistula? Yes, treatment with stem cells has had a success rate when used in perianal fistulas due to Crohn's Disease.
In zebrafish models of SURF1 mitochondrial disease, scientists have discovered drugs to prevent neurological decompensation.
New study advances intravitreal gene therapy platform to develop safe and effective therapies for visual loss in Usher Syndrome, rare disorder.
The study experiments shed light on a rare example of how autism-associated mutation could altered nuclear dynamics.
A genotype-first approach to patient care involves selecting patients with specific genomic variants and then studying their traits and symptoms.